Real‑world data from over 14,000 users in France show that a tubeless insulin pump integrated with a cloud platform improved diabetes management metrics, according to a multicenter dataset. The study underscores the clinical value of closed‑loop connectivity and large data capture for therapy optimization. In parallel, Dexcom reported a Q3 revenue beat but delivered conservative 2026 guidance and disclosed prior G7 sensor issues; the stock dropped sharply on investor reaction. Management said G7 issues were largely resolved, but guidance and supply concerns drove the market reaction. The juxtaposition of strong real‑world performance for cloud‑enabled devices and investor sensitivity to product issues highlights the sector’s dependence on reliable sensor performance, regulatory approvals, and scalable distribution. Device makers and payers will weigh real‑world outcome data against manufacturing and guidance risks when evaluating market projections.